Literature DB >> 19946934

Quetiapine treatment and improved cognitive functioning in borderline personality disorder.

Frederique Van den Eynde1, Sofie De Saedeleer, Kris Naudts, Jemma Day, Caroline Vogels, Cornelis van Heeringen, Kurt Audenaert.   

Abstract

OBJECTIVE: We aimed to assess whether executive functioning improved over time in a sample of borderline personality disorder (BPD) subjects that took part in a quetiapine treatment trial.
METHODS: Performance on the following neurocognitive tasks was assessed at enrolment and at the end of the 12 weeks quetiapine treatment: Trail Making Task, Word Fluency Task and Tower of London Task. Forty-one BPD patients were recruited, of whom 32 completed the trial. An intention-to-treat analysis with a mixed linear model was applied.
RESULTS: The data show that participants significantly improved on most executive functioning measures. Patients' scores decreased significantly (mean [SD] difference; p-value) on the Trail Making Task Part A (11.7 [2.3]; p < 0.0001), Part B (51.8 [9.2]; p < 0.0001) and 'B minus A' (40.1 [8.2]; p < 0.0001), on a Phonological (15.9 [1.6]; p < 0.0001) and Semantic (9.8 [1.1]; p < 0.0001) Verbal Fluency tasks, and on the Tower of London total correct score (2.5 [0.4]; p < 0.0001), total move score (29.5 [4.5]; p < 0.0001) and total time (172.9 [35.8]; p < 0.0001).
CONCLUSIONS: In this study we have demonstrated that executive functioning in BPD is improved after treatment with quetiapine. Neurocognitive measures of executive functioning should be considered as valuable outcomes in the study of treatment efficacy in BPD. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19946934     DOI: 10.1002/hup.1075

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

Review 1.  A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder.

Authors:  Ella Hancock-Johnson; Chris Griffiths; Marco Picchioni
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Quetiapine improves response inhibition in alcohol dependent patients: a placebo-controlled pilot study.

Authors:  Nathasha Moallem; Lara A Ray
Journal:  Pharmacol Biochem Behav       Date:  2011-10-20       Impact factor: 3.533

3.  Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability.

Authors:  Silvio Bellino; Paola Bozzatello; Camilla Rinaldi; Filippo Bogetto
Journal:  Depress Res Treat       Date:  2011-08-04

4.  Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).

Authors:  Márcio G Soeiro-DE-Souza; Vasco Videira Dias; Giovanni Missio; Vicent Balanzá-Martinez; Leandro Valiengo; André F Carvalho; Ricardo Alberto Moreno
Journal:  Exp Ther Med       Date:  2015-01-23       Impact factor: 2.447

5.  Second-generation antipsychotic use in borderline personality disorder: What are we targeting?

Authors:  Adrian Wasylyshen; Andrew M Williams
Journal:  Ment Health Clin       Date:  2016-03-08

Review 6.  Current Clinical Psychopharmacology in Borderline Personality Disorder.

Authors:  Antonio Del Casale; Luca Bonanni; Paride Bargagna; Francesco Novelli; Federica Fiaschè; Marco Paolini; Francesca Forcina; Gaia Anibaldi; Francesca Natalia Cortese; Alessia Iannuccelli; Barbara Adriani; Roberto Brugnoli; Paolo Girardi; Joel Paris; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.